Sarepta to tap into CRISPR treatment potential

Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Broad Institute enters talks for CRISPR licensing pool

11 July 2017 The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents.

Americas

EPO to grant UC, Berkeley CRISPR patent

28 March 2017 The European Patent Office has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.

More on this story

Americas

Broad Institute enters talks for CRISPR licensing pool

11 July 2017 The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents.

Americas

EPO to grant UC, Berkeley CRISPR patent

More on this story

Americas

Broad Institute enters talks for CRISPR licensing pool

11 July 2017 The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents.

Americas

EPO to grant UC, Berkeley CRISPR patent